Smith+Nephew Archives - Medical Design Sourcing

Smith+Nephew sales are up 7% as 12-point plan progresses

Smith+Nephew (NYSE: SNN) + shares dipped today on fourth-quarter results that included nearly 7% sales growth year-over-year.

Shares of SNN fell 2% to $27.97 apiece in late-afternoon trading.

The London-based orthopedic giant posted sales of $1.458 million in the quarter. That marked 6.8% growth compared to the same period a year ago.

Smith+Nephew says it continues to make progress on its 12-point plan, seeing it translate into financial outcomes. That dates back to 2022, when the company outlined aims to transform itself with this plan. It aims to improve execution and drive strategy for growth. That includes fixing orthopedics, improving productivity and accelerating wound management and sports medicine growth.

The company highlighted its innovation strategy driving higher growth and delivering a pipeline of new products. Its acquisition of CartiHeal in particular strengthened the company’s leader…

The biggest stories from AAOS 2024

The American Academy of Orthopaedic Surgeons’ annual meeting offers ortho tech companies the chance to present their latest innovations, and this year’s AAOS 2024 was no exception.

The event, running Feb. 12–16 in San Francisco, saw important announcements from companies including Stryker, Smith+Nephew, Osso VR and more.

Here are some highlights from AAOS 2024:

A new app for Stryker’s Mako The Mako robotic-assisted surgery system. [Image courtesy of Stryker]The world’s largest orthopedic device company says its Mako surgical robot for ortho procedures continues to drive growth, Stryker ended 2023 with 60% of its knee replacement procedures and 34% of its hip replacements in the U.S. performed using the robotic system.

Now, Stryker says it wants to further extend a surgeon’s Mako SmartRobotics experience in and beyond the operating room. The company used AAOS 2024 to highlight its myMako app for Apple Vision Pro and iPhone.

Wh…

Smith+Nephew kicks off Aetos shoulder system launch at AAOS

The Aetos shoulder system. [Image courtesy of Smith+Nephew]Smith+Nephew (NYSE: SNN) + announced today that it fully launched its Aetos shoulder system in the U.S. with additional FDA clearances.

Aetos originally received FDA clearance in June 2023, bolstering the company’s upper extremity portfolio. London-based Smith+Nephew designed Aetos to restore patients’ range of motion and help minimize arthritic shoulder pain. The system features the Aetos Meta Stem designed for maximizing stability preserving bone and maintaining patient anatomy.

Smith+Nephew announced the commercial rollout at AAOS, taking place this week in San Francisco.

Full commercial availability for Aetos comes along with FDA clearance for its use with AtlasPlan 3D planning software and patient-specific instrumentation for total shoulder arthroplasty.

More about the Smith+Nephew Aetos shoulder system

Aetos is indicated for both anatomic…

Smith+Nephew to show off new AI features for its Cori surgical robot

The Cori system with Personalized Planning and RI.Insights. [Image courtesy of Smith+Nephew]Smith+Nephew (NYSE: SNN) + announced today that it plans to “provide a glimpse into the future” of its Cori surgical robotic system.

The Cori handheld robotic system supports the entire continuum of care in knee arthroplasty. It offers a comprehensive solution for navigated total hip arthroplasty as well.

Cori’s new image-agnostic, robotic-assisted solution could further help personalize surgery and advance efficiencies. The London-based orthopedic giant feels the updates to the system help to optimize performance across its orthopedic reconstruction portfolio.

Smith+Nephew plans to offer a look at the new solutions at AAOS 2024 in San Francisco this week.

The new features from Smith+Nephew include the RI.KNEE software to enable joint line restoration and improve outcomes. Smith+Nephew first unveiled…

Smith+Nephew unveils expanded sports medicine portfolio

The CartiHeal Agili-C implant and Regeneten bioinductive implant. [Images courtesy of Smith+Nephew]Smith+Nephew (NYSE: SNN) + today announced plans to unveil new sports medicine technologies this week.

The London-based orthopedic giant plans to premiere its newly acquired CartiHeal Agili-C cartilage repair implant. Bioventus had a deal in place to acquire CartiHeal and its technology last summer. However, when that fell through, Smith+Nephew executed a $180 million buyout (with a potential $150 million to add on) in November 2023.

Smith+Nephew also plans to unveil the Regeneten bioinductive implant alongside the CartiHeal technology. All this is taking place at the AAOS Annual Meeting in San Francisco this week. The company says its technologies could transform soft tissue repair treatments compared to the current standard of care.

CartiHeal’s Agili-C implant is an accessible treatment for osteochondral lesio…

Study backs Smith+Nephew Regeneten bioinductive rotator cuff implant

[Image from Smith+Nephew]Smith+Nephew (NYSE: SNN) + today announced positive results for its Regeneten bioinductive implant from a randomized controlled trial.

Data, published online in Arthroscopy, highlighted the success of Regeneten against the standard of care. One-year results found that medium and large full-thickness rotator cuff tears repaired and augmented with the implant had better tendon healing.

Regeneten provides a patient-centric treatment supporting the body’s natural healing process. The aim is for the collagen-based implant to change the course of tear progression, aid return to normal activity and reduce re-tears compared to conventional surgery. Smith+Nephew previously reported positive data on the implant in September 2022.

About the data from Smith+Nephew

Results included a significantly lower re-tear rate, at 8.3% with Regeneten against 25.8% with the standard of care. The implant also had a …

How can medtech companies innovate their business models?

From left: Veronica Acurio, Gio Di Napoli, Brian Montgomery and Simran Sabharwal talked business model innovation at AdvaMed’s The MedTech Conference.

In an ever-changing medtech space, how do companies keep up with the pace of change? How do companies adjust and innovate their business models to reflect that?

Leaders from some of medtech’s biggest names attempted to answer some questions around that at AdvaMed’s The MedTech Conference yesterday. (Want to find out more? Leaders from major medical device companies will discuss innovation in surgical robotics, diabetes tech, cardiovascular and neurovascular tech, oncology and more at DeviceTalks West, Oct. 18–19 in Santa Clara. Register here.)

A panel on “Disruptive Business Models in Medtech: The Next Frontier of Value-Centric Innovation” included:

Veronica Acurio, president of the Medical Solutions division, 3M; Gio Di Napoli, president of the GI operating unit at Medtronic; B…

How Medtronic, Zimmer Biomet and Smith+Nephew approach medtech M&A

From left, Geoff Martha, Rachel Ellingson and Deepak Nath spoke on a panel about M&A.

In a year with some massive acquisitions in medtech, there are still questions around an overall drop in M&A activity.

According to Pete Cataldo, managing director and medtech head of Truist, deal volume in the sector fell 65% in the first half of 2023. However, despite high interest rates and a volatile stock market, there appears to remain a market for medtech M&A.

For instance, this year brought the merger of orthopedic giants Globus Medical and Nuvasive and Johnson & Johnson’s $16.6 billion acquisition of Abiomed.

The possibilities for M&A are still there, and some of medtech’s biggest names are taking different approaches.

At AdvaMed’s The MedTech Conference, Cataldo moderated a panel called “Medtech M&A: Trends, Strategies, and Opportunities.” It featured Medtronic CEO Geoff Martha, Zimmer Biomet SVP and…

State of the industry — Execs ‘more bullish than ever’ on medtech

From left: Kevin Lobo, Lisa Earnhardt, Deepak Nath, Bernard Zovighian. All spoke about the state of the industry at The MedTech Conference.

Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are.

The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized in 2021 were wiped out by the end of 2022.

However, leading medtech executives, including Stryker CEO Kevin Lobo, only see upwards.

“I feel as bullish as I’ve ever felt in my time in medtech,” Lobo declared.

Lobo, Abbott EVP of Medical Devices Lisa Earnhardt, Smith+Nephew CEO Deepak Nath and Edwards CEO Bernard Zovighian all have positive outlooks for the space. They outlined their views on a panel based around the EY report Monday at T…

Smith+Nephew launches hip arthroplasty system in India

The OR3O dual mobility system. [Image courtesy of Smith+Nephew]Smith+Nephew (NYSE: SNN) + announced today that it launched its OR3O dual mobility system for hip arthroplasty in India.

The London-based orthopedic device maker designed OR3O for use in primary and revision hip arthroplasty. Compared to traditional solutions, dual mobility implants have a smaller-diameter femoral head. It locks into a larger polyethylene insert, increasing stability, reducing dislocation risk and improving range of motion.

Smith+Nephew initially launched OR3O in the U.S. in 2020.

While most hip implants utilize a cobalt chrome (CoCr) liner with CoCr/SST or ceramic head balls, OR3O uses a different bearing surface. The system utilizes Smith+Nephew’s advanced Oxinium DH for its liner and proprietary Oxinium on XLPE for its femoral head and polyethylene inserts. This eliminates the modular CoCr liner and/or CoCr head ball from the c…

The 10 largest orthopedic device companies in the world

The goal of Stryker’s Mako robotic-arm assisted surgery is to provide more predictable outcomes. [Image courtesy of Stryker]

Two of the world’s largest orthopedic device companies expect accelerated revenue growth this year.

Stryker and Zimmer Biomet both upped their 2023 guidance during recent earnings calls, a sign that orthopedic procedures are bouncing back from the COVID-19 pandemic.

GlobalData predicted earlier this year that the recovery will lift the ortho devices market to nearly $50 billion this year. The question is whether companies can continue the momentum. Stryker and ZB are betting on innovation, building arrays of products and services around their surgical robotics systems and surgical planning and digital health tools.

During Zimmer Biomet’s second-quarter earnings call, CEO Bryan Hanson noted that ZB has 40 planned product launches between this year and the end of 2025, the …

The 10 largest orthopedic device companies in the world

The goal of Stryker’s Mako robotic-arm assisted surgery is to provide more predictable outcomes. [Image courtesy of Stryker] Two of the world’s largest orthopedic device companies expect accelerated revenue growth this year.

Stryker (NYSE: SYK) + and Zimmer Biomet (NYSE: ZBH) + both upped their 2023 guidance during recent earnings calls, a sign that orthopedic procedures are bouncing back from the COVID-19 pandemic.

GlobalData predicted earlier this year that the recovery will lift the ortho devices market to nearly $50 billion this year. The question is whether companies can continue the momentum. Stryker and ZB are betting on innovation, building arrays of products and services around their surgical robotics systems and surgical planning and digital health tools.

During Zimmer Biomet’s second-quarter earnings call, CEO Bryan Hanson noted that ZB has 40 planned product …